- uMotif is a scalable and engaging patient-centred data capture platform for modern research.
- uMotif is the leading modern data capture platform for research, that patients love to use.
- The company was founded in London, United Kingdom in 2012 by CPO Ben James and CEO Bruce Hellman.
uMotif has an app that allows patients to monitor themselves for treatments or drug trials, which then feeds into a platform, allowing a much faster approach to clinical studies.
uMotif is a scalable and engaging patient-centred data capture platform for modern research. The platform provides patient-facing technology to capture data for clinical research initiatives and also captures compliant, validated patient-generated e-consent, eCOA, ePRO, PROM, and PREM data for researchers and clinicians, allowing pharmaceutical companies to capture rich health data across a range of conditions.
More from MedTech
- How AI is Revolutionising Brain Surgery and Other Medical Practices
- Wearable Health Devices: A Step into the Future
- Dr Owain Rhys Hughes: ‘3 vital lessons I’ve learned as a healthtech founder’
- How MedTech Can Help Tackle The NHS Backlog
- How HealthTech Can Help Relieve Pressure On The NHS And Empower People To Take Control Of Their Own Health
- David Hancock: Why Interoperability In Healthcare Is Vital To Relieving Pressure On The NHS
- Cera Launches Flu Tracker And Treatment System To Protect Older People and The NHS This Winter
- Flow Neuroscience Receives Series A Funding To Make Self-Managed Medical Device Available Globally
uMotif raises £5M from AlbionVC
In September 2020, uMotif announced that it has raised £5 million in a Series A investment round led by existing U.K. investor AlbionVC, with participation from Oslo-based DNV-GL and existing angel investors. This latest round takes it to a total funding size of £7.5 million.
The platform is sold into life sciences companies which are gradually replacing centralised studies where patients have to go to a site, such as a hospital, to submit their data. The trend has been catalysed by COVID-19. The platform is now used by studies taking place in 26 countries, from clinical to real-world settings, and across more than 25 therapeutic areas — from dermatology and rare disease to oncology and cardiology. The largest study involved more than 13,000 participants tracking their pain levels and the weather. This was featured on the BBC and published in Nature.
Its competitors are almost entirely U.S.-based and include organisations such as SnapIOT, Medable and Clinical Ink, as well as other large platform companies.